World

WHO teams successfully reach Kamal Adwan Hospital in Gaza, deliver medical supplies

Nov 06, 2024

Geneva [Switzerland], November 6: Dr. Rik Peeperkorn, World Health Oraganisation (WHO) Representative for the Occupied Palestinian Territory, affirmed that the organisation's teams were able to reach Kamal Adwan Hospital in the Gaza Strip, successfully delivering medical and surgical supplies despite extremely difficult conditions.
The team also provided 150 blood units, 20,000 litres of fuel, food, and water, and transferred 25 patients along with 37 companions to Al Shifa Hospital.
In a press conference held today via video link from Gaza with journalists in Geneva, the WHO official stated that only three doctors remain at the hospital, which was accessed the day before yesterday (Sunday). Among them are two paediatricians and a general practitioner, along with 30 nurses and 120 inpatients.
Regarding Al Awda Hospital, he noted that the WHO mission was also able to reach it on the same day, transferring five patients and five caregivers to Al Shifa Hospital. He emphasised that no surgical procedures could be performed there due to a lack of electricity, warning that this could lead to the complete shutdown of the hospital.
Source: Emirates News Agency

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025